NASDAQ:EXAC - Exactech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.25 0.00 (0.00 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$49.25
Today's Range$49.25 - $49.30
52-Week Range$23.75 - $50.95
Volume255,640 shs
Average Volume182,742 shs
Market Capitalization$707.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
Exactech logoExactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company's segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.

Receive EXAC News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNASDAQ:EXAC
CUSIP30064E10
Phone+1-352-3771140

Debt

Debt-to-Equity Ratio0.06
Current Ratio4.08
Quick Ratio2.09

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio37.88
P/E Growth3.66

Sales & Book Value

Annual Sales$257.57 million
Price / Sales2.76
Cash Flow$2.5413 per share
Price / Cash19.38
Book Value$16.51 per share
Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$160,000.00
Net Margins4.72%
Return on Equity4.62%
Return on Assets3.82%

Miscellaneous

Employees733
Outstanding Shares14,420,000

The Truth About Cryptocurrencies

Exactech (NASDAQ:EXAC) Frequently Asked Questions

What is Exactech's stock symbol?

Exactech trades on the NASDAQ under the ticker symbol "EXAC."

How were Exactech's earnings last quarter?

Exactech, Inc. (NASDAQ:EXAC) issued its earnings results on Monday, October, 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.23 by $0.03. The medical equipment provider earned $61.40 million during the quarter, compared to analysts' expectations of $61.78 million. Exactech had a net margin of 4.72% and a return on equity of 4.62%. View Exactech's Earnings History.

What price target have analysts set for EXAC?

3 equities research analysts have issued twelve-month target prices for Exactech's shares. Their predictions range from $49.00 to $49.00. On average, they anticipate Exactech's share price to reach $49.00 in the next year. View Analyst Ratings for Exactech.

Who are Exactech's key executives?

Exactech's management team includes the folowing people:
  • R. William Petty M.D., Executive Chairman of the Board (Age 74)
  • David W. Petty, Chief Executive Officer, President and Director (Age 50)
  • Joel C. Phillips CPA, Chief Financial Officer, Executive Vice President, Treasurer (Age 49)
  • Bruce E. Thompson, Senior Vice President , General manager- Biologics and Spine Division (Age 59)
  • Gary J. Miller Ph.D., Executive Vice President - Research and Development (Age 69)
  • Donna M. Edwards, Vice President, Legal and General Counsel (Age 44)
  • Betty A. Petty, Vice President - Administration, Corporate Secretary (Age 74)
  • James G. Binch, Independent Director (Age 69)
  • W. Andrew Krusen Jr., Independent Director (Age 68)
  • William B. Locander Ph.D., Independent Director (Age 73)

Has Exactech been receiving favorable news coverage?

Headlines about EXAC stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exactech earned a news sentiment score of 0.12 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Exactech?

Shares of EXAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exactech's stock price today?

One share of EXAC stock can currently be purchased for approximately $49.25.

How big of a company is Exactech?

Exactech has a market capitalization of $707.53 million and generates $257.57 million in revenue each year. Exactech employs 733 workers across the globe.

How can I contact Exactech?

Exactech's mailing address is 2320 NW 66th Ct, GAINESVILLE, FL 32653-1630, United States. The medical equipment provider can be reached via phone at +1-352-3771140 or via email at [email protected]


MarketBeat Community Rating for Exactech (EXAC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Exactech and other stocks. Vote "Outperform" if you believe EXAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.